[
  {
    "ts": null,
    "headline": "Do These 3 Healthcare Stocks Need a Checkup?",
    "summary": "These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?",
    "url": "https://finnhub.io/api/news?id=e04e817cdc30e85f467211c9ca0f7d962bb4691cc3dbcdb72f31ac9ffa69158e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764969900,
      "headline": "Do These 3 Healthcare Stocks Need a Checkup?",
      "id": 137715587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?",
      "url": "https://finnhub.io/api/news?id=e04e817cdc30e85f467211c9ca0f7d962bb4691cc3dbcdb72f31ac9ffa69158e"
    }
  },
  {
    "ts": null,
    "headline": "Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?",
    "summary": "Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.",
    "url": "https://finnhub.io/api/news?id=b02f50f17748fcf8a54159364f3058740bc22ea1012e6286e6f2d162204820b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764945720,
      "headline": "Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?",
      "id": 137697248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.",
      "url": "https://finnhub.io/api/news?id=b02f50f17748fcf8a54159364f3058740bc22ea1012e6286e6f2d162204820b1"
    }
  },
  {
    "ts": null,
    "headline": "Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026",
    "summary": "Praxis Precision Medicines, Inc. soars after study success and pipeline wins. Explore key milestones, projections, and investor outlook. Click for more on PRAX.",
    "url": "https://finnhub.io/api/news?id=42aeafe71a65488e107dd4e4e15db143420253437ff9b553249ed169a03d9e08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764945563,
      "headline": "Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026",
      "id": 137706311,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1944434984/image_1944434984.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Praxis Precision Medicines, Inc. soars after study success and pipeline wins. Explore key milestones, projections, and investor outlook. Click for more on PRAX.",
      "url": "https://finnhub.io/api/news?id=42aeafe71a65488e107dd4e4e15db143420253437ff9b553249ed169a03d9e08"
    }
  },
  {
    "ts": null,
    "headline": "Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use",
    "summary": "Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.",
    "url": "https://finnhub.io/api/news?id=9bbc987499a21bd87a50ccae690aa0fb96aa253fc7885b7a4066b0ff103c6bc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764928800,
      "headline": "Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use",
      "id": 137697249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.",
      "url": "https://finnhub.io/api/news?id=9bbc987499a21bd87a50ccae690aa0fb96aa253fc7885b7a4066b0ff103c6bc5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets FDA Expanded Approval of Breyanzi",
    "summary": "Bristol Myers Gets FDA Expanded Approval of Breyanzi",
    "url": "https://finnhub.io/api/news?id=8b73bbe10937e6c9294488866d25719140bc1cfde11ed5fe1b0c1468a3336418",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764915360,
      "headline": "Bristol Myers Gets FDA Expanded Approval of Breyanzi",
      "id": 137702093,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Gets FDA Expanded Approval of Breyanzi",
      "url": "https://finnhub.io/api/news?id=8b73bbe10937e6c9294488866d25719140bc1cfde11ed5fe1b0c1468a3336418"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "url": "https://finnhub.io/api/news?id=0f819f952a0d7b7fb76f6b95a17fb6fb1c03dfd1c6341c2bd4913cd4a7036b87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764897300,
      "headline": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
      "id": 137692778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
      "url": "https://finnhub.io/api/news?id=0f819f952a0d7b7fb76f6b95a17fb6fb1c03dfd1c6341c2bd4913cd4a7036b87"
    }
  }
]